Effects of compound short-acting oral contraceptives combined with insulin sensitizers on maternal and infant pregnancy outcomes in patients with polycystic ovary syndrome

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052703

Enrollment

Unknown

Registered

2021-11-03

Start date

2021-11-01

Completion date

Unknown

Last updated

2022-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

Experimental group:Compound short-acting oral contraceptive combined with insulin sensitizer

Control group:None

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for PCOS in Rotterdam in 2013; 2. Aged between 18-35 years; 3. Those who have informed consent, volunteer to be tested, have reproductive needs, and can track pregnancy outcomes; 4. Have not used any hormonal drugs and drugs that have an effect on endocrine and glucose and lipid metabolism in the 3 months before the study and during the study period.

Exclusion criteria

Exclusion criteria: 1. Reproductive tract malformations; 2. Combined with other endocrine disorders, such as diabetes, abnormal thyroid function; 3. Combined with serious heart, liver, kidney and other diseases; 4. Combined with malignant tumor; 5. Mental disorder; 6. Those who were lost to follow-up.

Design outcomes

Primary

Measure	Time frame
adverse pregnancy outcommes;neonatal complications;pregnancy complications;height;	—

Secondary

Measure	Time frame
weight;	—

Countries

China

Contacts

Public ContactLi Li

13631446859@163.com+86 13631446859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026